The company was cleared to begin a Phase I/II trial of its lead candidate, a therapeutic vaccine that can potentially treat and prevent recurrence of KRAS-mutated cancers.
The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
The Spanish firm also expects to release clinical data on its early-stage, next-generation sequencing-based colorectal cancer test in the first half of 2021.
The study, which showed that the disease may not only result from tobacco exposure as previously thought, could lay the groundwork for targeted therapies.
The startup biotech has spent four years researching PRDM genes in various cancers and is coming out of stealth mode with a lead candidate in lung cancer.
The Universities of Southampton and Leeds will lead the project with participation from Johnson & Johnson, Roche, Oncimmune, BC Platforms, Inivata, and NHS England.
